Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tohru Takeuchi

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
Arthritis Research & Therapy|June 17, 2020
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Journal of Internal Medicine|September 22, 2025
Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort studyShogo Matsuda, Takuya Kotani, Daisuke Nishioka, et al.
Rheumatology International|October 18, 2019
The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort studyKoichi Murata, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|April 12, 2019
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Plos One|May 9, 2019
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|May 8, 2019
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Modern Rheumatology|November 10, 2025
A Multicentre, Prospective Registry of Patients with Systemic Sclerosis in Japan: Baseline Patient CharacteristicsMasataka Kuwana, Shinji Watanabe, Tohru Takeuchi, et al.
Rheumatology (Oxford, England)|October 24, 2025
Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort studyYuri Hiramatsu, Takuya Kotani, Eri Nakamura, et al.
Clinical Rheumatology|January 30, 2021
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Modern Rheumatology|September 16, 2022
Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort studyHidehiko Makino, Takuya Kotani, Kenichiro Hata, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
Arthritis Research & Therapy|June 17, 2020
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Journal of Internal Medicine|September 22, 2025
Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort studyShogo Matsuda, Takuya Kotani, Daisuke Nishioka, et al.
Rheumatology International|October 18, 2019
The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort studyKoichi Murata, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|April 12, 2019
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Plos One|May 9, 2019
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|May 8, 2019
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Modern Rheumatology|November 10, 2025
A Multicentre, Prospective Registry of Patients with Systemic Sclerosis in Japan: Baseline Patient CharacteristicsMasataka Kuwana, Shinji Watanabe, Tohru Takeuchi, et al.
Rheumatology (Oxford, England)|October 24, 2025
Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort studyYuri Hiramatsu, Takuya Kotani, Eri Nakamura, et al.
Clinical Rheumatology|January 30, 2021
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
Modern Rheumatology|September 16, 2022
Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort studyHidehiko Makino, Takuya Kotani, Kenichiro Hata, et al.
Pageof 13